Clinical TrialJun 1, 2026, 08:32 AM
IN8bio DeltEx DRI mPFS 13.0 months, mOS >19.5 months in GBM
AI Summary
IN8bio, Inc. announced updated clinical data from its INB-200 Phase 1 and INB-400 Phase 2 studies for newly diagnosed glioblastoma (GBM) at the ASCO Annual Meeting. Repeat dosing of its DeltEx DRI therapy achieved a median progression-free survival (mPFS) of 13.0 months, nearly double the 6.6 months for standard-of-care (SOC) alone. The median overall survival (mOS) for repeat-dose patients exceeded 19.5 months, significantly higher than the 13.2 months for SOC, with 43% of repeat-dose patients alive at 24 months compared to 20% for SOC. The therapy was well tolerated and demonstrated a positive impact on the tumor microenvironment and immune reconstitution.
Key Highlights
- Repeat dosing of DeltEx DRI achieved a median progression-free survival (mPFS) of 13.0 months in newly diagnosed glioblastoma (GBM) patients.
- This mPFS is nearly double the 6.6 months observed in patients receiving standard-of-care (SOC) alone.
- Median overall survival (mOS) for repeat-dose patients currently exceeds 19.5 months (+48%) and has not yet been reached.
- Final mOS for patients receiving only SOC was 13.2 months.
- Approximately 43% of repeat-dose patients remained alive at 24 months, compared to 20% of SOC patients.
- Intracranially delivered DeltEx DRI was generally well tolerated, with no dose-limiting toxicities, cytokine release syndrome, or neurotoxicity.
- Translational analyses showed DeltEx DRI treatment drove a cold-to-hot tumor microenvironment shift.
- Higher total doses of DeltEx DRI increased cumulative "gamma-delta" T cell and CD4+ levels, correlating with improved overall survival.
Price Impact
More from INAB